BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15490423)

  • 1. Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Mignani R
    Semin Nephrol; 2004 Sep; 24(5):532-6. PubMed ID: 15490423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal transplantation in patients with Fabry disease.
    Sessa A; Meroni M; Battini G; Maglio A; Nebuloni M; Tosoni A; Panichi V; Bertagnolio B
    Nephron; 2002 Jun; 91(2):348-51. PubMed ID: 12053080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal ultrastructural findings in Anderson-Fabry disease.
    Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
    J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
    Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
    Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
    Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
    G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.
    Tosoni A; Nebuloni M; Zerbi P; Vago L; Comotti C; Sessa A
    Ultrastruct Pathol; 2005; 29(3-4):203-7. PubMed ID: 16036875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.